Radiation Dose Escalation Study for Advanced Liver Cancer
Phase I Trial of Radiation Dose Escalation for Locally Advanced Hepatocellular Carcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pathologically confirmed or clinically diagnosed HCC
- Surgically unsectable or medically inoperable diseases, or surgery declined by the patient
- Solitary intrahepatic lesion with diameter bigger than 5 cm, without extrahepatic and/or distant metastases
- Associated with cirrhosis of Child-Pugh A
- Karnofsky performance status (KPS) of ≥ 70
- Normal renal function and adequate bone marrow reservation
- Tolerate active breathing control (ABC)
Exclusion Criteria:
- Child-Pugh B or C liver cirrhosis score
- Previous radiotherapy to the liver
- Indistinct tumor boundary in CT/MRI image
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: arm 1
Arm I: tumor diameter more than 5 cm and less than 10 cm.
|
The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I .
Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy.
Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II.
Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy.
Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
|
|
Other: arm 2
Arm II: tumor diameter no less than 10 cm.
|
The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I .
Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy.
Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II.
Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy.
Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Toxicity was graded using the CTCAE 3.0. Dose-limiting toxicity was defined as acute ≥ grade 3 hepatic or gastrointestinal toxicity, or any grade 5 treatment-related adverse event, or late complication of radiation-induced liver disease.
Time Frame: 4 months
|
4 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
1,2 and 3 years survival
Time Frame: 4 years
|
4 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Guoliang Jiang, M.D., Fudan University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LCR-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.